1652 / 1835
Transplant BRAVE study
A prospective, multicenter, international phase I/II clinical trial consisting of
a dose-finding phase 1 part, followed by a single-arm, non-randomized
phase 2 part.
Rationale:
•
Combining Brentuximab Vedotin with DHAP chemotherapy in patients
with Hodgkin lymphoma (HL) refractory to first line chemotherapy or in
first relapse is expected to induce a
significantly higher (metabolic) CR
rate prior to consolidation with BEAM
•
Comparison with
published data on DHAP salvage only
.
•
Increasing metabolic CR rate prior to consolidation with high dose
chemotherapy and autologous SCT is expected to improve PFS and OS